Journal
CLINICAL ORAL INVESTIGATIONS
Volume 26, Issue 1, Pages 1089-1093Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00784-021-04349-x
Keywords
Cytokines; Prednisone; Recurrent aphthous stomatitis; Saliva; T helper cell
Categories
Funding
- National Natural Science Foundation of China [82074502, 82101008]
- Shanghai Municipal Health Committee [20174Y0098]
Ask authors/readers for more resources
This study found that systemic prednisone treatment significantly reduced the levels of cytokine expression in the saliva of minor RAS patients and promoted a Th1/Th2 balance.
Objectives To investigate the changes of T helper cell (Th)1/Th2-related cytokine expression in the saliva of minor recurrent aphthous stomatitis (RAS) patients before and after treatment with systemic prednisone. Methods A total of 101 patients with RAS and 15 participants with normal oral mucosa as controls were enrolled in this study. The levels of cytokine expression in the whole unstimulated saliva were examined using a multiplex bead-based cytometric bead array before and after prednisone treatment at a starting dose of 15 mg/day. Results The levels of salivary interleukin (IL)-4, IL-5, IL-6, IL-10, interferon (IFN)-gamma, and tumor necrosis factor-alpha (TNF-alpha) in RAS patients were significantly higher than those of the normal controls (all P < 0.001). Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Moreover, the IFN-gamma to IL-4 ratio (mean: 26.9) was significantly (P < 0.001) decreased after treatment, which almost returned to normal (mean: 24.4; P > 0.05). Conclusion This preliminary study demonstrates for the first time that prednisone exerts a significant therapeutic role against RAS through decreasing salivary cytokine levels and promoting a Th1/Th2 balance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available